We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Developing World Could Be the New IVD Growth Region

By LabMedica International staff writers
Posted on 18 Oct 2011
The next big growth opportunity in in-vitro diagnostics (IVD) is possibly the developing world where high-temperature and scarce water conditions require rapid easy-to-use IVD tests. More...


A new report from Kalorama Information (Rockville Pike, MD, USA) by diagnostic market analyst Shara Rosen and diagnostic consulting network president Brendan O’Farrell describes a quarter-billion dollar market in the next five years for tests that can detect infectious diseases such as malaria and TB—but also rarer diseases like leptospirosis and chikungunya.

The incidence of TB, malaria, hepatitis, and, in particular, HIV/AIDS continues to increase, with HIV/AIDS and TB likely to account for the overwhelming majority of deaths from infectious diseases in developing countries by 2020. Shara Rosen commented, “For the past 10-15 years politicians and aid agencies have come to understand that infectious diseases are not merely causes of suffering and death but also significant barriers to economic development.”

Increased funding for infectious disease diagnostics by groups such as the Bill and Melinda Gates Foundation, the Program for Appropriate Technology in Health (PATH; Seattle, WA, USA) and The Foundation for Innovative New Diagnostics (FIND; Geneva, Switzerland) is helping to develop a new generation of sophisticated test platforms that are designed to meet the needs of low resource environments.

The response of the international community towards the problem has created a market. The report cites a 13% growth rate for sales of point-of-care (POC) tests that treat these most pressing health needs. This is greater than Kalorama forecasts for most areas of the POC diagnostics market.

Shara Rosen added, “There is a huge need for user-friendly, highly specific and reliable technologies for rural and underserved communities worldwide, and that is where the opportunity lies.”

There are at least 75 vendors worldwide that market rapid test kits for emerging infectious diseases. The current market leaders are companies that have invested in sophisticated new technologies and those that have established relationships with governments and international aid agencies.

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare; as well as a full range of custom research services.

Related Links:
Kalorama Information
Bill and Melinda Gates Foundation
The Foundation for Innovative New Diagnostics


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.